Clinical trials: Lymphoma (Hodgkin's and Non-Hodgkin's)
Non-Hodgkin's Lymphoma (NHL)
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
The primary objective of the study is to determine the efficacy, as measured by overall response (complete response + partial response) of bendamustine in combination with ofatumumab in previously untreated patients with indolent…
- Trial name
- NCT01108341
- Testing
- Bendamustine hydrochloride, Ofatumumab
- Where
- 39 sites in United States, Belgium and 1 more
- Volunteers
- 50 people
- Sponsor
- Cephalon
Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma
- Trial name
- NCT00006473
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin's Disease, Lymphoma, Non-Hodgkin
Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma
Radiation therapy has a well-established role in the treatment of Hodgkin's Disease and non-Hodgkin's Lymphoma. With technological developments, 3-D Dimensional (3D) planning has evolved as a highly precise treatment planning…
- Trial name
- NCT00232440
- Testing
- BodyFIX
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumors and Non-Hodgkin's Lymphoma
A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine
In the First-in-Human, JWAA trial, the LY2780301 displayed a favourable safety profile, a high pharmacokinetic exposure and the ability to decrease pS6.
- Trial name
- INPAKT (NCT02018874)
- Testing
- LY2780301, Gemcitabine
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Non-Hodgkin's Lymphoma
A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma
This single-arm, open-label, multi-centre study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in patients with follicular non-Hodgkin's lymphoma with minimal residual disease after autologous…
- Trial name
- NCT01388959
- Testing
- rituximab [MabThera/Rituxan]
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients with relapsed…
- Trial name
- NCT00002880
- Testing
- Etoposide phosphate
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Diffuse Large B-Cell Lymphoma
Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma
This is a multicenter study phase II, open-label for cardiopathic patients affected by Non-Hodgkin's lymphoma diffuse large B cell CD20 + grade IIIb follicular.
- Trial name
- NCT01009970
- Testing
- Rituximab, Cyclophosphamide, Vincristine
- Where
- 32 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT00109824
- Testing
- decitabine, valproic acid, pharmacological study
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003262
- Testing
- bleomycin sulfate, filgrastim, Stanford V regimen
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Lymphoma
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
The goal of this clinical research study is to find out how well the drug Zolinza (vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) to treat…
- Trial name
- NCT00787527
- Testing
- Zolinza (vorinostat), Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Non-Hodgkin's Lymphoma
A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma
This research study is evaluating Enterade, a supplement, as a possible treatment for the side effects caused by Stem Cell Transplant.
- Trial name
- NCT02919670
- Testing
- Enterade, Standard Supportive Care
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Dana-Farber Cancer Institute
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
- Trial name
- NCT07439653
- Testing
- TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent
- Where
- 9 sites in United States
- Volunteers
- 155 people
- Sponsor
- TORL Biotherapeutics, LLC
Lymphoma, Leukemia
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
This research is being done to learn more about reduced-intensity bone marrow transplantation (BMT), also known as a "mini" transplant for patients with blood cancers, using bone marrow from a relative.
- Conditions
- Lymphoma, Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01135329
- Testing
- Fludarabine, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma
Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
RATIONALE: Inserting the gene for RevM10 into a person's peripheral stem cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
- Trial name
- NCT00003942
- Testing
- RevM10 gene, RevM10/polAS gene, in vitro-treated peripheral blood stem cell transplantation
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Systemix
DLBCL
A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects
This is a prospective international, multi-center, randomized, double-blind controlled study designed to assess and compare the pharmacokinetics, pharmacodynamics and the safety of MabThera® and TL011, in combination with CHOP in…
- Trial name
- NCT01205737
- Testing
- TL011, Rituximab
- Where
- 41 sites in Bulgaria, Estonia and 8 more
- Volunteers
- 186 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Non Hodgkin's Follicular Lymphoma
VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma
The aim of this study was to evaluate the efficacy and safety of the combination of Velcade and Rituximab in patients with relapsed Non Hodgkin's Follicular Lymphoma.
- Trial name
- NCT01830465
- Testing
- Bortezomib (VELCADE), Rituximab
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Gruppo Italiano Studio Linfomi
Childhood Brain Tumor, Childhood Hodgkin Lymphoma
Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
This clinical trial studies dietary and exercise interventions in preventing cardiovascular disease in younger survivors of childhood cancer.
- Conditions
- Childhood Brain Tumor, Childhood Hodgkin Lymphoma, Childhood Non-Hodgkin Lymphoma, Malignant Childhood Neoplasm
- Trial name
- NCT02000986
- Testing
- Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy
- Sponsor
- Virginia Commonwealth University
Primary Cutaneous Lymphoma
TreAtments and outComes in paTients With prImary CutAneous Lymphoma
In order to further improve the diagnosis and treatment level of primary cutaneous lymphoma in China, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for primary…
- Trial name
- TACTICAL (NCT05518851)
- Where
- 5 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Peking University First Hospital
Lymphoma, Follicular
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma
Patients will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I 131 Tositumomab. Pharmacokinetic data for the primary endpoint analysis will be derived from testing done on blood samples drawn at 12 timepoints…
- Trial name
- NCT00315731
- Testing
- Follicular Lymphoma
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.